Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KLK3 | P07288 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25336894 | 0.85 | IKBKB (0.52) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL30668822 | 0.85 | IKBKB (0.52) | TDP1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL28845264 | 0.77 | IDO1 (0.49) | ALDH1A1GAA | |
| SCHEMBL18685343 | 0.76 | ALDH1A1 (0.43) | TDP1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL25983826 | 0.76 | PIN1 (0.41) | TDP1SMN1; SMN2ALDH1A1KDM4EMEN1 | |
| SCHEMBL18662655 | 0.76 | CLK1 (0.74) | TDP1SMN1; SMN2TSHRALDH1A1KDM4E | |
| SCHEMBL30435423 | 0.76 | CLK1 (0.74) | TDP1SMN1; SMN2TSHRALDH1A1KDM4E | |
| SCHEMBL9550119 | 0.75 | TDP1 (0.78) | TDP1SMN1; SMN2TSHRMAPK1ALDH1A1 | |
| SCHEMBL3396168 | 0.74 | KMO (0.35) | TDP1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL29716088 | 0.74 | TDP1 (0.47) | TDP1SMN1; SMN2TSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | TDP1 48/4885SMN1; SMN2 2860/4885TSHR 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.